India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
This article was originally published in PharmAsia News
Executive Summary
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck